CN101278981B - Medicament for treating upper respiratory tract infection in children and preparation method thereof - Google Patents
Medicament for treating upper respiratory tract infection in children and preparation method thereof Download PDFInfo
- Publication number
- CN101278981B CN101278981B CN2007100389768A CN200710038976A CN101278981B CN 101278981 B CN101278981 B CN 101278981B CN 2007100389768 A CN2007100389768 A CN 2007100389768A CN 200710038976 A CN200710038976 A CN 200710038976A CN 101278981 B CN101278981 B CN 101278981B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- herba
- medicine
- respiratory tract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses a medicine used for treating infantile upper respiratory tract infection, which is prepared by scutellaria, radix isaatidis, andelion, mint, notopterygium, thin douche, periostracum didadae, bombyx batryticatus, common dayflower, Radix Rumicis Japonici, atractylodes and glycyrrhiz according to a certain weight proportion. The raw medicines undergo the processes of soaking, decoction, filtration and condensation to prepare oral liquid. The medicine used for treating infantile upper respiratory tract infection has the effects of diverting outer wind, clearing heat, detoxification and evidently improving the symptoms and signs of the infantile upper respiratory tract infection. The medicine is mainly applicable to treating the infantile upper respiratory tract infection caused by wind-heat, such as tonsillitis and pharyngitis and so on.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of infant upper respiratory tract infection and preparation method thereof, belong to the field of Chinese medicines.
Background technology
Upper respiratory tract infection is modal disease in children's's period, how to be caused by viral infection, and mainly show as heating, nasal obstruction, watery nasal discharge, cough etc., differentiation of symptoms and signs for classification of syndrome mostly is " interior pattern of fever ".Clinical antiviral drugs Western medicine commonly used mainly contains ribavirin at present, but this medicine side effect is more, as irritated, nauseating, diarrhoea, liver function injury etc.; Chinese medicine mainly contains SHUANGHUANGLIAN KOUFUYE, but its curative effect is still not satisfactory.The inventor finds that in the clinical practice of long-term treatment infant upper respiratory tract infection the antiviral drugs of compositions such as Chinese traditional drug taraxacum herb, Radix Isatidis, Radix Scutellariae, Herba Menthae, Rhizoma Et Radix Notopterygii, Periostracum Cicadae, Bombyx Batryticatus, Herba Commelinae is rapid-action in treatment child virus upper respiratory tract infection, good effect can obviously be improved many symptoms, the sign of infant upper respiratory tract infection.
Summary of the invention
The technical issues that need to address of the present invention just provide a kind of Chinese medicine composition of effective treatment infant upper respiratory tract infection.
Another technical problem that the present invention need solve provides the preparation method of this Chinese medicine composition.
Traditional Chinese medicinal composition raw materials thing of the present invention selects Radix Scutellariae, Radix Isatidis, Herba Taraxaci, Herba Menthae, Rhizoma Et Radix Notopterygii, Semen Sojae Preparatum, Periostracum Cicadae, Bombyx Batryticatus, Herba Commelinae, Radix Rumicis Crispi, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae to make up, and is used for the treatment of diseases such as upper respiratory tract infection amygdala inflammation due to the affection due to external wind and heat, pharyngitis.
Tender and lovely, the striae of the skin and muscles being loose of children's's internal organs is subject to exopathogen invasion, and children's be a pure-yang constituent again, on pathology heat-transformation also fast, clinical ailment said due to cold or exposure is held concurrently, and heat symptom-complex is more sees.So adopt stronger Radix Scutellariae, Radix Isatidis, the Herba Taraxaci of heat-clearing and toxic substances removing ability.The Radix Scutellariae bitter cold is gone into lung, intestine and small intestine warp, specially rushes down part of the body cavity above the diaphragm housing the heart and lungs lung-heat, contain baicalin, have the heat clearing away bacteriostasis, extracorporeal bacteria inhibitor test has inhibitory action to influenza virus, Diplococcus pneumoniae, bordetella pertussis, and peripheral vessels there is dilating effect, can removes experimental heating; The Radix Isatidis bitter cold focuses on heat-clearing and toxic substances removing, imitates with clearing throat, and the disease of aphtha of the mouth and tongue has wider antimicrobial spectrum and antivirus action; The Herba Taraxaci bitter but sweet flavor is cold, go into liver stomach two warps, merit with heat-clearing and toxic substances removing, not only can be used for the surgery carbuncle sore, can control the strongly fragrant lung of internal medicine pathogenic heat again, can control laryngopharynx swelling and pain with the Radix Isatidis compatibility, Herba Taraxaci is the conventional medicament of heat-clearing and toxic substances removing, in recent years studies show that it has good anti-infectious function, can be made into various dosage forms, be widely used in clinical various infectious disease.
Wind being the primary exopathogen, normal double mutually with pathogenic heat, go into by mouth and nose or fur, in attack lung meridian, a series of wind heat table disease appears.Ancients say: " evil in table, antiperspirant can be also." so induce sweat with wind and heat dispersing with Herba Menthae, Rhizoma Et Radix Notopterygii, Semen Sojae Preparatum, giving treatment in accordance with the tendency of pathological change draws heresy and shows out.Herba Menthae is hot cool, goes into lung liver two warps, and dispelling wind and heat pathogens, clearing throat effect are arranged, and modern pharmacology proof Herba Menthae contains volatile oil (Oleum menthae), can act on sensory nerve ending, can make sensory paralyses and plays the pain relieving effect, improves the part symptom of having sore throat; Rhizoma Et Radix Notopterygii Eradicates wind, relieving exterior syndrome antipyretic effect is fine, cooperate Radix Isatidis, Herba Taraxaci treatment treatment wind heat table disease, and the back of generally bringing down a fever does not have the phenomenon of generating heat once again; Semen Sojae Preparatum is cool in nature, and bitter in the mouth, suffering attach to the lung and stomach meridians, have induce sweat, effect that relieving restlessness, a surname are sent out hot and suffocating.
Children's's the liver being liable to excess is subject to exopathogen and causes liver-wind and produce hyperpyrexia convulsion.Periostracum Cicadae, Bombyx Batryticatus two medicines are all gone into lung, liver two warps, but at lung dispelling wind and heat pathogens, clearing throat, but go into the liver suppressing the hyperactive liver to relieve the wind syndrome, the effect of tool spasmolytic, can prevent that infantile hyperpyrexia faints from fear, the effect that the two has the dissipating phlegm and resolving masses spasmolytic again is used for clinical variability cough, spasmodic cough also has tall and erect the effect; Herba Commelinae is sweet cold, but heat-clearing and toxic substances removing diuresis, but all fever caused by exogenous pathogens or febrile disease heating are not moved back person's single and are used, it is little and go that early on the books in the Chinese medicine textbook, it can make, and high febrile lysis, urine amount increase, heat is moved whiz, and body temperature may rise again after its shortcoming was drug withdrawal, use with the other medicines compatibility in the drug composition in the present invention, the part that can compensate its defect both can make hyperpyrexia speed move back, and unlikely again hyperpyrexia gos up; Radix Rumicis Crispi bitter cold slight fever, cooling blood for hemostasis contains anthraquinone derivative such as chrysophanol, emodin etc., and bacteriostasis is arranged, and has the merit of purging heat to relax the bowels, and pathogenic heat are gone out from stool, gives heresy with outlet, auxiliary bringing down a fever.
Children's's the spleen tending to insufficiency usually, the product injuring spleen-stomach of bitter cold is used the Rhizoma Atractylodis Macrocephalae so add, and helps fortune with spleen invigorating, avoids bitter cold damage the foundation of acquired constitution, reaches eliminating evil and does not hinder just purpose; Radix Glycyrrhizae property is flat, sweet in the mouth, the function of tool spleen reinforcing, lung moistening, detoxifcation, coordinating the actions of various ingredients in a prescription, and Radix Glycyrrhizae mainly plays the effect of coordinating the actions of various ingredients in a prescription herein.
Each constituent content of Chinese medicine composition of the present invention has better curative effect in the following weight parts scope:
3～18 parts of Radix Scutellariaes, 5～30 parts of Radix Isatidis, 5～30 parts of Herba Taraxacis, 0.5～3 part of Herba Menthae, 2～12 parts of Rhizoma Et Radix Notopterygiis, 3～18 parts of Semen Sojae Preparatums, 1.5～9 parts of Periostracum Cicadaes, 3～18 parts of Bombyx Batryticatus, 5～30 parts of Herba Commelinaes, 3～18 parts of Radix Rumicis Crispi, 3～18 parts of the Rhizoma Atractylodis Macrocephalaes, 0.5～3 part in Radix Glycyrrhizae.
Be preferably: 6 parts of Radix Scutellariaes, 10 parts of Radix Isatidis, 10 parts of Herba Taraxacis, 1 part of Herba Menthae, 4 parts of Rhizoma Et Radix Notopterygiis, 6 parts of Semen Sojae Preparatums, 3 parts of Periostracum Cicadaes, 6 parts of Bombyx Batryticatus, 10 parts of Herba Commelinaes, 6 parts of Radix Rumicis Crispi, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 1 part in Radix Glycyrrhizae.
The preparation method of Chinese medicine composition of the present invention is as follows:
With the Herba Menthae of described weight proportion add suitable quantity of water fully moistening after, add water and make it submergence, decocted filtration, filtrate for later use 15 minutes; All the other of medicinal residues and described weight proportion ten medicine simply merge, and add water and surpass powder 2-4cm, decoct twice, 1.5 hours for the first time, 1 hour for the second time, decocting liquid filtered, merging filtrate left standstill more than 12 hours, got supernatant concentration to about 600ml, add 5 times of amount 90% ethanol, precipitate 48 hours, get supernatant and reclaim ethanol, add above-mentioned standby Herba Menthae extracting solution, add sucrose 200g, sodium benzoate 2g again, stir evenly promptly.
This Chinese medicine composition mainly plays the merit of dispelling wind to relieve the exterior syndrome, heat-clearing and toxic substances removing, can obviously improve many symptoms, the sign of infant upper respiratory tract infection.
The specific embodiment
Below further set forth the beneficial effect of Chinese medicine composition of the present invention, but do not limit the scope of the invention by the test example.
Clinical trial
1, diagnose and include in standard:
(1) tcm diagnosis standard (drafting in 1994) according to national Chinese medicine management board " traditional Chinese medical science disease diagnosis criterion of therapeutical effect ":
1. based on diseases such as fever with chills, nasal obstruction watery nasal discharge, sneezes, the coughs of holding concurrently, can accompany vomiting, diarrhoea or hyperpyrexia convulsion more;
2. all had in 4 o'clock, be more common in the Winter-Spring, often fall ill because of the weather cataclysm;
3. the blood leukocytes sum is normal or on the low side, and neutrophilic granulocyte reduces, and lymphocyte increases relatively, and mononuclear cell increases.
(2) Western medicine diagnose standard (drafting) according to the anti-scientific research association informal discussion emblem standard that cures cold in the whole nation
1. clinical manifestation: based on local symptom, General Symptoms can have or be not obvious
General Symptoms: general malaise, fear of cold, heating, headache, giddy, extremity and aching pain in waist and back etc.;
Local symptom: nasal obstruction, watery nasal discharge, sneeze, cough sometimes, pharyngalgia, hoarseness, shed tears etc.
2. Clinical typing
● light-duty: as to have tangible upper respiratory tract infection symptoms, nasal discharge obviously to increase, the slight or nothing of General Symptoms, natural history 2-4 days;
● medium-sized: local symptom is light-dutyer serious, and has certain General Symptoms, and as fear of cold, heating, headache, general malaise etc., natural history is about 1 week;
● heavy type: tangible upper respiratory tract infection symptoms and General Symptoms are arranged, as heating, general malaise, inappetence, lassitude, headache, often above various more remarkable with cough, sniffle.
(3) the disconnected standard of Syndrome in TCM marquis disease (the national Chinese medicine of foundation management board " traditional Chinese medical science disease diagnosis criterion of therapeutical effect " nineteen ninety-five)
Wind heat is violated table:
Primary symptom: heating is empty, aversion to cold is light, pharynx is red;
Deuteropathy: antiperspirant or lossless is arranged, and headache, nasal obstruction, the thick tears of stream, cough, dysphoria with smothery sensation are thirsty, red tongue thick fur Huang, floating and rapid pulse.
(4) cardinal symptom scalar quantization (seeing Table 1)
Table 1 infantile fever caused by exogenous pathogens symptom scalar quantization table
| Symptom | Gently | In | Heavy |
| Heating | 37.5-38℃ | 38-39℃ | >39℃ |
| Aversion to cold | Slightly feel aversion to cold, parent is snuggled up in happiness | Obviously be afraid of cold, must add clothing | Shivering, add clothing does not still understand |
| Pharynx is red and swollen | Pharyngeal mild hyperaemia | Isthmus faucium and the congested flushing of pharynx rear wall | Pharyngeal hyperemia, tonsil swelling |
| Nasal obstruction | Slight nasal obstruction does not influence breathing | Nasal obstruction, breathing snore | Obstructed, the mouth breathing of having a stuffy nose |
| Watery nasal discharge | A small amount of nasal mucus is arranged once in a while | Be interrupted watery nasal discharge | Watery nasal discharge is more than, amount is many |
| Sneeze | Idol has sneeze | Be interrupted sneeze | Sneeze repeatedly |
| Cough | More shallow, the idol of coughing has a cough | Be interrupted cough, number of times not frequently | Again and again cough, influence sleep |
| Cough up phlegm | A small amount of sputum is arranged when coughing once in a while | Expectorant is arranged, a small amount of rale in the larynx when coughing | Abundant expectoration when coughing, gurgling with sputum is filtered |
| Asthenia | Fatigue is arranged slightly, do not influence activity | Asthenia is obvious, is reluctant activity | Tired mind is unable to leave the bed |
| Nausea | Have nauseatingly slightly, do not influence feed | Nausea constantly, feed reduces | Nauseating tending to vomit can not be taken food |
Illustrate: picture of the tongue, pulse condition (fingerprint) specifically describe, and do not score.
(5) include standard in
1. meet the disconnected standard of doctor trained in Western medicine disease
2. meet Syndrome in TCM marquis diagnostic criteria
3. the course of disease≤3 day
(6) exclusion standard
1. severe malnutrition, or with other cardiovascular, lung, serious systemic disease patient such as harmonization of the stomach hemopoietic system is to this medicine allergy sufferers;
2. suppurative tonsillitis, bronchitis, bronchiolitis, pneumonia etc.
(7) withdraw from standard
● anaphylaxis occurs, sb.'s illness took a turn for the worse that severely adverse event person maybe may take place or take place, and judges according to the doctor to stop clinical research person, promptly ends this case clinical research, increase the weight of the state of an illness and then make invalid case and handle;
● in research process, some complication, complication or special physiological take place and change in the experimenter, may be not suitable for continuing to participate in researcher, judge according to the doctor stop clinical research person, promptly end this case clinical research;
● the experimenter is unwilling to proceed clinical research in the clinical research process, propose to withdraw from the requirement of clinical research to physician, and this case can withdraw from clinical research.
(8) termination criteria
1. serious adverse events appears;
2. find in the research that research medication curative effect is too poor, do not have clinical research and be worth;
3. in clinical research conceptual design or the enforcement important deviation having taken place, has been difficult to estimate drug influence.
(9) case comes off
1. the reason that comes off may be:
● experimenter's compliance is poor, research compliance＜80% or 120%, or the Chinese and western drugs that merge to use this programme to ban use of, or midway change dressings voluntarily or dosing;
● break away from naturally in the observation, lose visit person, comprise that therapeutic process is effective, but can not complete whole process, so that the not congruent safe judgement person that affects the treatment of data;
● serious adverse events or complication take place, and should not continue to accept to study and by the case that given up the study of.
The processing of the case that 2. comes off
● after the experimenter came off, researcher should be striven for visiting, and reservation is followed up a case by regular visits to, phone, and the method for mail etc. is got in touch with the experimenter as far as possible, and the inquiry reason writes down last administration time, finishes the evaluation item that can finish.
● because of drug allergy, untoward reaction, fail to respond to any medical treatment and withdraw from the case of research, researcher should be given and the corresponding treatment measure according to practical situation.
2, physical data
Picked at random 150 routine patients, inpatient's 34 examples wherein, door emergency case 116 examples are divided into 2 groups, test group 100 examples, matched group 50 examples.Two groups are at aspects such as age, sex, the course of disease, the state of an illness relatively, there was no significant difference, and concrete condition is as follows:
(1) the infant age ratio: see Table 2
Table 2 liang group infant age distribution relatively
Two groups of infant age ratios are than P〉0.05%, not statistically significant, tool comparability.
(2) the infant sex ratio: see Table 3
Table 3 liang group infant sex distribution situation relatively
Table 3 as seen, two groups of infant gender difference and not statistically significant (P〉0.05) show two groups of infant sex composition zero differences, the tool comparability.
(3) course of disease time ratio: see Table 4
Table 4 liang group infant course of disease situation relatively
Table 4 as seen, two groups of infant course of disease difference no difference of science of statistics (P〉0.05) show that two groups of infant courses of disease are similar, the tool comparability.
(4) severity extent relatively: see Table 5
Table 5 liang group infant state of an illness situation relatively
| The distribution group | The example number | Light-duty | ％ | Medium-sized | ％ | Heavy | ％ |
| Test group | 100 | 9 | 9％ | 46 | 46％ | 45 | 45％ |
| Matched group | 50 | 4 | 8％ | 25 | 50％ | 21 | 42％ |
The visible two groups of infant state of an illness difference no difference of science of statistics of table 5 (P〉0.05), show that two groups of infant state of an illness are similar, the tool comparability.
(5) heating relatively sees Table 6
Table 6 liang group infant heating situation relatively
| Group | The example number | Do not generate heat | <38 ℃? | <39 ℃? | >39 ℃? | On average (X ± 1) | ||||
| Test group | 100 | ?2 | 2％ | 17 | 17％ | 62 | 62％ | 19 | 19％ | 38.4+0.69 |
| Matched group | 50 | ?1 | 2％ | 10 | 20％ | 29 | 58％ | 10 | 20％ | 38.3±0.65 |
The visible two groups of infant the degree of heat situations of table 6 similar (P〉0.05) show that two groups of infant state of an illness are similar, the tool comparability.
3, Therapeutic Method
(1) trial drug, specification
Investigational agent: Chinese medicine composition of the present invention is made antivirus oral liquid, authentication code: medicament N (91)-023 (child) is defended in Shanghai, produce by Shanghai City Children Hospital, main component is Radix Scutellariae, Radix Isatidis, Herba Taraxaci, Herba Menthae, Rhizoma Et Radix Notopterygii, Semen Sojae Preparatum, Periostracum Cicadae, Bombyx Batryticatus, Herba Commelinae, Radix Rumicis Crispi, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, specification 10ml/ props up, room temperature preservation.
The contrast medicine: SHUANGHUANGLIAN KOUFUYE, authentication code: medicine standard I230022924, Harbin medicine company limited is produced, and main component is Flos Lonicerae, Radix Scutellariae, Fructus Forsythiae, and 10ml/ props up, room temperature preservation.
(2) method of administration
Test group: take antivirus oral liquid, 1～3 years old, each 1, every day 2 times; 4～6 years old, each 1, every day 3 times; 7～12 years old, each 1, every day 3～4 times.The Chinese and western drugs that influences its therapeutic effect of other treatment flu of during studying, stopping using.
Matched group: take SHUANGHUANGLIAN KOUFUYE, dosage is the same.
One week was a course of treatment.
4, efficacy assessment standard:
Comprehensive Assessment is carried out in variation according to the body temperature of infant and cardinal symptom, sign before and after the treatment.
Annotate: computing formula (nimodipine method) is: [integration before (integration before the treatment-treatment back integration) ÷ treatment] * 100%.
(1) general curative effect criterion:
Clinical recovery: the temperature recovery normal (37 ℃ of axil temperature are no longer gone up) in 24-48 hour of taking medicine, clinical symptoms, sign disappears, and unusual physical and chemical index recovers normal, integrated value minimizing 〉=95%;
Produce effects: the temperature recovery of taking medicine in 24-48 hour is normal, main clinic symptoms, and the sign integrated value reduces 〉=70%;
Effectively: the temperature recovery of taking medicine in 48-72 hour is normal, main clinic symptoms, and the sign integrated value reduces 〉=30%;
Invalid: do not reach above standard person, integrated value reduces less than 30%.
(2) cardinal symptom curative effect determinate standard:
Recovery from illness: the cardinal symptom complete obiteration, integrated value reduces 〉=95%;
Produce effects: the sign integrated value reduces 〉=70%;
Effectively: the sign integrated value reduces 〉=30%;
Invalid: do not reach above standard person, integrated value reduces less than 30%.
5, therapeutic outcome
(1) clinical curative effect analysis sees Table 7
Table 7 liang group efficacy analysis
Table 7 as seen, test group clinical recovery, produce effects, effectively, total effective rate is respectively 41%, 30%, 22% and 93%.Matched group then is respectively 26%, 22%, 32% and 80%.Two groups of differences are according to statistical procedures, and P＜0.05 shows that test group antivirus oral liquid curative effect is better than matched group.
(2) improve the heating efficacy analysis: see Table 8
Table 8 a liang group is brought down a fever effect relatively
| Symptom | Group | Before the treatment | After the treatment | Compare in the group | Compare between group | ||||||
| Heating | ≥39 ℃ | ≥38 ℃ | ≥37 ℃ | Normally | ≥39 ℃ | ≥38 ℃ | ≥37 ℃ | Normally | |||
| Test group | 19 | 62 | 17 | ?2 | ?0 | ?2 | ?9 | 89 | <0.001 | >0.05 | |
| Matched group | 10 | 29 | 10 | ?1 | ?0 | ?3 | ?8 | 39 | <0.01 |
The two groups of infants in table 8 visible treatment back are brought down a fever obviously, and the normal ratio of test group temperature recovery surpasses matched group, but not statistically significant.
Table 9 liang group fever time relatively
| Group | The example number | 1 day | 2 days | 3 days | 4-5 days | 5 days | Average natural law |
| Test group | 100 | 29 | 38 | 26 | 5 | 2 | 2.13±1.17 |
| Matched group | 50 | 9 | 13 | 13 | 12 | 3 | 2.58±1.35 |
The visible test group of table 9 natural law of on average bringing down a fever is 2.13 ± 1.17, matched group 2.58 ± 1.35, and two groups of difference tool statistical significances (P＜0.05) show that test group brings down a fever faster than matched group.
(3) change relatively symptom according to traditional Chinese medical science primary symptom and the traditional Chinese medical science time disease situation: see Table 10
Table 10 liang group traditional Chinese medical science primary symptom change situation relatively
The visible two groups of infants treatment of table 10 back heating, nasal obstruction symptom are clearly better, and two groups of situations are similar; And pharynx is red and swollen, and is more obvious with the test group improvement, and two groups of differences have statistics and select meaning, shows that red and swollen improvement of test group pharynx is better than matched group.
The table 11 liang group traditional Chinese medical science time disease improvement situation relatively
| Group | The example number | Symptom XX before the treatment | Treatment back symptom XX |
| Test group | 100 | 9.28±3.21 | 3.74+0.92 ***△ |
| Matched group | 50 | 9.03±3.41 | 3.98±1.35 *** |
Annotate: compare before and after the group internal therapy
* *P＜0.01; Compare △ P＜0.05 between group before and after the treatment
The inferior disease situation of the preceding two groups of infants flu of the visible treatment of table 11 is similar, and obvious decline (P＜0.01) is arranged after the treatment, but two groups of treatment time disease situation differences also have statistical significance, shows that the inferior disease improvement of test group treatment flu is better than matched group.
6. safety analysis
(1) safety evaluatio standard
The I level: safety, there is not any untoward reaction; Safety indexes is checked no abnormal.
II level: compare safety,, do not need to do any processing and can continue administration if any untoward reaction; Security inspection is no abnormal.
III level: safety issue is arranged, moderate untoward reaction is arranged, can continue administration after processing; Or safety takes stopgap measures and checks that mile abnormality is arranged.
IV level: because of untoward reaction gives up the study of; Or the safety indexes inspection has obviously unusual.
(2) safety evaluatio: see Table 12
Table 12 liang group safety evaluatio
Further illustrate the preparation method of medicine of the present invention by the following examples
Embodiment: Radix Scutellariae 180g, Radix Isatidis 300g, Herba Taraxaci 300g, Herba Menthae 30g, Rhizoma Et Radix Notopterygii 120g, Semen Sojae Preparatum 180g, Periostracum Cicadae 90g, Bombyx Batryticatus 180g, Herba Commelinae 300g, Radix Rumicis Crispi 180g, Rhizoma Atractylodis Macrocephalae 180g, Radix Glycyrrhizae 30g.
Preparation method: with the Herba Menthae of described weight proportion add suitable quantity of water fully moistening after, add water and make it submergence, decocted filtration, filtrate for later use 15 minutes; All the other of medicinal residues and described weight proportion ten medicine simply merge, and add water and surpass powder 2-4cm, decoct twice, 1.5 hours for the first time, 1 hour for the second time, decocting liquid filtered, merging filtrate left standstill more than 12 hours, got supernatant concentration to about 600ml, add 5 times of amount 90% ethanol, precipitate 48 hours, get supernatant and reclaim ethanol, add above-mentioned standby Herba Menthae extracting solution, add sucrose 200g, sodium benzoate 2g again, stir evenly promptly.
Claims (3)
1. medicine for the treatment of infant upper respiratory tract infection is characterized in that this medicine made by the raw material of following weight portion: 3～18 parts of Radix Scutellariaes, 5～30 parts of Radix Isatidis, 5～30 parts of Herba Taraxacis, 0.5～3 part of Herba Menthae, 2～12 parts of Rhizoma Et Radix Notopterygiis, 3～18 parts of Semen Sojae Preparatums, 1.5～9 parts of Periostracum Cicadaes, 3～18 parts of Bombyx Batryticatus, 5～30 parts of Herba Commelinaes, 3～18 parts of Radix Rumicis Crispi, 3～18 parts of the Rhizoma Atractylodis Macrocephalaes, 0.5～3 part in Radix Glycyrrhizae.
2. medicine according to claim 1, wherein the consumption of each crude drug is: 6 parts of Radix Scutellariaes, 10 parts of Radix Isatidis, 10 parts of Herba Taraxacis, 1 part of Herba Menthae, 4 parts of Rhizoma Et Radix Notopterygiis, 6 parts of Semen Sojae Preparatums, 3 parts of Periostracum Cicadaes, 6 parts of Bombyx Batryticatus, 10 parts of Herba Commelinaes, 6 parts of Radix Rumicis Crispi, 6 parts of the Rhizoma Atractylodis Macrocephalaes, 1 part in Radix Glycyrrhizae.
3. according to the preparation method of claim 1 or 2 described medicines, may further comprise the steps: with the Herba Menthae of described weight proportion add suitable quantity of water fully moistening after, add water and make it submergence, decocted filtration, filtrate for later use 15 minutes; All the other of medicinal residues and described weight proportion ten medicine simply merge, and add water and surpass powder 2-4cm, decoct twice, 1.5 hours for the first time, 1 hour for the second time, decocting liquid filtered, merging filtrate left standstill more than 12 hours, got supernatant concentration to about 600ml, add 5 times of amount 90% ethanol, precipitate 48 hours, get supernatant and reclaim ethanol, add above-mentioned standby Herba Menthae extracting solution, add sucrose 200g, sodium benzoate 2g again, stir evenly promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100389768A CN101278981B (en) | 2007-04-02 | 2007-04-02 | Medicament for treating upper respiratory tract infection in children and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007100389768A CN101278981B (en) | 2007-04-02 | 2007-04-02 | Medicament for treating upper respiratory tract infection in children and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101278981A CN101278981A (en) | 2008-10-08 |
| CN101278981B true CN101278981B (en) | 2011-09-07 |
Family
ID=40011768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007100389768A Active CN101278981B (en) | 2007-04-02 | 2007-04-02 | Medicament for treating upper respiratory tract infection in children and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101278981B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102512610A (en) * | 2011-12-25 | 2012-06-27 | 杨庆菊 | Traditional Chinese medicinal preparation for treating tonsillitis |
| CN102552347A (en) * | 2012-02-01 | 2012-07-11 | 杨军 | Preparation method of common dayflower herb heat-clearing antivirus raw juice oral liquid |
| CN103655693A (en) * | 2012-09-26 | 2014-03-26 | 张献奎 | Traditional Chinese medicine preparation for treating acute tonsillitis |
| CN116270853A (en) * | 2022-08-24 | 2023-06-23 | 清华德人西安幸福制药有限公司 | Application of Thermoyanning in preparing medicine for treating children or teenagers SARS-CoV-2 asymptomatic or mild infection |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1131550A (en) * | 1995-03-17 | 1996-09-25 | 黄国杰 | Pearl oral liquor capable of clearing away heart-fire |
-
2007
- 2007-04-02 CN CN2007100389768A patent/CN101278981B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1131550A (en) * | 1995-03-17 | 1996-09-25 | 黄国杰 | Pearl oral liquor capable of clearing away heart-fire |
Non-Patent Citations (3)
| Title |
|---|
| 农光平.小儿上呼吸道感染.《健康生活》.2005,(第4期), * |
| 刘远顺.辨证治疗小儿急性上呼吸道感染113例.《实用中医药杂志》.2006,第22卷(第7期), * |
| 周秀芳.小儿感冒.《中国乡村医药》.1999,第6卷(第6期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101278981A (en) | 2008-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101461911B (en) | Chinese medicine oral capsule for treating gout | |
| CN101095736A (en) | Chinese traditional medicine composition for treating acute and chronic pharyngitis, tonsillitis and method of making the same | |
| CN106138360A (en) | A kind of Chinese medicine composition and preparation method thereof, application | |
| CN100389803C (en) | Chinese medicinal composition for treating wind-heat cold and preparation method thereof | |
| CN101244193A (en) | Traditional Chinese medicine for treating respiratory disease and method for preparing the same | |
| CN101278981B (en) | Medicament for treating upper respiratory tract infection in children and preparation method thereof | |
| CN101670011A (en) | Medicament for treating rheumatism and rheumatoid and preparation method thereof | |
| CN109954034A (en) | A kind of preparation method for treating chill, wind-heat, the drug of influenza and its oral solution | |
| CN103285218B (en) | Traditional Chinese medicine compound for treating spleen and kidney yang deficiency type constipation | |
| CN101023996B (en) | Chinese medicine for treating exogenous epidemic disease and anemopyretic cold | |
| CN103479932B (en) | One treats bronchitic Chinese medicine composition and preparation method thereof | |
| CN101322733B (en) | Chinese herbal medicine formulation for treating pollution lung disease | |
| CN104147194A (en) | Traditional Chinese medicine composition for treating chronic sinusitis | |
| CN104623379B (en) | A kind of pharmaceutical composition for the treatment of Hand-Food-Mouth Disease | |
| CN103623065A (en) | Medicine composition for treating influenza | |
| CN105879000A (en) | Pharmaceutic preparation for treating tonsillitis and application thereof | |
| CN101773620B (en) | Heat-clearing stranguria-treating drug | |
| CN1069053C (en) | Oral medicine for curing phlegm-heat cough | |
| CN103494924B (en) | Chinese medicine composition for treating damp-heat stagnation acne | |
| CN100457177C (en) | Chinese medicinal health-care preparation for cloaring lung, supplementing kidney | |
| CN102727614B (en) | Chinese-western medicine preparation for treating chronic obstructive pulmonary disease | |
| CN102198185B (en) | Medicament for rapidly treating chronic pharyngolaryngitis | |
| CN105362548A (en) | Traditional Chinese medicine for treating allergic asthma | |
| CN104958530A (en) | Traditional Chinese medicinal composition for treating infantile pneumonia | |
| CN105168860A (en) | Traditional Chinese medicine composite for treating infantile asthma and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |